HRP20210644T1 - Imunomodulatori za pet-snimanje - Google Patents
Imunomodulatori za pet-snimanje Download PDFInfo
- Publication number
- HRP20210644T1 HRP20210644T1 HRP20210644TT HRP20210644T HRP20210644T1 HR P20210644 T1 HRP20210644 T1 HR P20210644T1 HR P20210644T T HRP20210644T T HR P20210644TT HR P20210644 T HRP20210644 T HR P20210644T HR P20210644 T1 HRP20210644 T1 HR P20210644T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- tissues
- subject
- disease
- compound according
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title claims 2
- 239000002955 immunomodulating agent Substances 0.000 title 1
- 229940121354 immunomodulator Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 238000002600 positron emission tomography Methods 0.000 claims 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000003325 tomography Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/12—Arrangements for detecting or locating foreign bodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- High Energy & Nuclear Physics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (13)
1. Spoj formule (I):
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu x je cijeli broj od 1 do 8 i R je C1-C6alkil grupa.
2. Spoj prema patentnom zahtjevu 1 formule (II):
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu x je cijeli broj od 1 do 8 i R je C1-C6alkil grupa.
3. Spoj formule (III):
[image]
ili njegova farmaceutski prihvatljiva sol.
4. Spoj formule (IV):
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu x je cijeli broj od 1 do 8.
5. Spoj prema patentnom zahtjevu 4 formule (V):
[image]
ili njegova farmaceutski prihvatljiva sol.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5 ili njegova farmaceutski prihvatljiva sol za primjenu u dijagnosticiranju bolesti.
7. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema patentnom zahtjevu 6, pri čemu je bolest odabrana iz grupe koju čine solidni karcinomi, hematopoetski karcinomi, hematološki karcinomi, autoimuna bolest, neurodegenerativna bolest, kardiovaskularna bolest, i patogena infekcija.
8. Postupak za dobivanje snimke spoja prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu postupak obuhvaća:
a) administriranje spoja subjektu; i
b) snimanje in vivo distribucije spoja skeniranjem pozitronskom emisijskom tomografijom (PET).
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5 za primjenu u dobivanju snimke, pri čemu navedena primjena obuhvaća:
a) administriranje spoja subjektu; i
b) snimanje in vivo distribucije spoja skeniranjem pozitronskom emisijskom tomografijom (PET), pri čemu snimljena distribucija spoja ukazuje na prisustvo ili odsustvo bolesti.
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5 za primjenu u praćenju napredovanja bolesti kod subjekta, pri čemu navedena primjena obuhvaća:
(a) administriranje subjektu kome je to potrebno spoja koje se vezuje za ciljanu molekulu povezanu sa prisustvom bolesti u prvoj vremenskoj točki i dobivanje snimka najmanjeg dijela subjekta radi određivanja količine oboljelih stanica ili tkiva; i
(b) administriranje subjektu spoja u jednoj ili više sljedećih vremenskih točaka i dobivanje snimka najmanjeg dijela subjekta u svakoj vremenskoj točki; pri čemu dimenzija i lokacija oboljelih stanica ili tkiva u svakoj vremenskoj točki ukazuju na napredak bolesti.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5 za primjenu u kvantificiranju oboljelih stanica ili tkiva kod subjekta, pri čemu navedena primjena obuhvaća:
(a) administriranje subjektu koji ima bolesne stanice ili tkiva spoja koje se vezuje za ciljnu molekulu smještenu sa oboljelim stanicama ili tkivima; i
(b) detektiranje radioaktivnih emisija 18F u oboljelim stanicama ili tkivu,
pri čemu nivo i raspodjela radioaktivnih emisija u oboljelim stanicama ili tkivima je kvantitativna mjera oboljelih stanica ili tkiva.
12. Postupak za dobivanje kvantitativnog snimka tkiva ili stanica koje eksprimiraju PD-L1, pri čemu postupak obuhvaća kontakt stanica ili tkiva sa spojem prema patentnom zahtjevu 1 koje se vezuje za PD-L1, i detektiranje ili kvantificiranje tkiva koje eksprimira PD-L1 primjenom pozitronske emisijske tomografije (PET).
13. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 5.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338872P | 2016-05-19 | 2016-05-19 | |
| EP17728696.0A EP3458111B1 (en) | 2016-05-19 | 2017-05-17 | Pet-imaging immunomodulators |
| PCT/US2017/033004 WO2017201111A1 (en) | 2016-05-19 | 2017-05-17 | Pet-imaging immunomodulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20210644T1 true HRP20210644T1 (hr) | 2021-05-28 |
| HRP20210644T8 HRP20210644T8 (hr) | 2021-06-25 |
Family
ID=59021563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210644TT HRP20210644T8 (hr) | 2016-05-19 | 2021-04-23 | Imunomodulatori za pet-snimanje |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11103605B2 (hr) |
| EP (2) | EP3827849A1 (hr) |
| JP (1) | JP6953444B2 (hr) |
| KR (1) | KR102378288B1 (hr) |
| CN (1) | CN109414514B (hr) |
| AU (1) | AU2017268291B2 (hr) |
| BR (1) | BR112018073642A2 (hr) |
| CA (1) | CA3024844A1 (hr) |
| CY (1) | CY1124241T1 (hr) |
| DK (1) | DK3458111T3 (hr) |
| EA (1) | EA038019B1 (hr) |
| ES (1) | ES2864091T3 (hr) |
| HR (1) | HRP20210644T8 (hr) |
| HU (1) | HUE054306T2 (hr) |
| IL (1) | IL262962B (hr) |
| LT (1) | LT3458111T (hr) |
| MA (1) | MA53402A (hr) |
| MX (1) | MX2018014028A (hr) |
| PL (1) | PL3458111T3 (hr) |
| PT (1) | PT3458111T (hr) |
| RS (1) | RS61742B1 (hr) |
| SG (1) | SG11201810177VA (hr) |
| SI (1) | SI3458111T1 (hr) |
| WO (1) | WO2017201111A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| US11857352B2 (en) | 2016-09-06 | 2024-01-02 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| CA3045466A1 (en) | 2016-12-01 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| KR20240023665A (ko) * | 2016-12-23 | 2024-02-22 | 더 존스 홉킨스 유니버시티 | Pd-l1 발현에 기반한 종양 및 면역 세포 영상화 |
| MA46814B2 (fr) | 2017-02-10 | 2022-09-30 | Regeneron Pharma | Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet |
| US11066445B2 (en) | 2017-06-23 | 2021-07-20 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of PD-1 |
| WO2019023148A1 (en) | 2017-07-24 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | ANTI-CD8 ANTIBODIES AND USES THEREOF |
| KR20200058506A (ko) | 2017-10-03 | 2020-05-27 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
| CN110504017B (zh) * | 2019-07-30 | 2022-06-10 | 哈尔滨医科大学 | 一种示踪剂的制备和使用方法 |
| WO2021188480A1 (en) * | 2020-03-16 | 2021-09-23 | Bristol-Myers Squibb Company | Immunomodulators |
| US20220405917A1 (en) * | 2021-06-18 | 2022-12-22 | Case Western Reserve University | Combination of features from biopsies and scans to predict prognosis in sclc |
| WO2024129479A2 (en) * | 2022-12-12 | 2024-06-20 | Merck Sharp & Dohme Llc | Cyclic peptides as pet imaging agents of granzyme b |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5128119A (en) | 1989-06-12 | 1992-07-07 | Immunomedics, Inc. | Methods for technetium/rhenium labeling of f(ab1)2 fragments |
| US5328679A (en) | 1988-04-01 | 1994-07-12 | Immunomedics, Inc. | Methods for technetium/rhenium labeling of proteins |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| IL113610A0 (en) | 1994-06-03 | 1995-08-31 | Immunomedics Inc | A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same |
| US5746996A (en) | 1994-06-03 | 1998-05-05 | Immunomedics, Inc. | Thiolation of peptides for radionuclide-based radiodetection and radiotherapy |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US5753206A (en) | 1995-06-07 | 1998-05-19 | Immunomedics, Inc. | Radiometal-binding analogues of luteinizing hormone releasing hormone |
| JP2000510119A (ja) | 1996-05-03 | 2000-08-08 | イムノメディクス，インコーポレイテッド | ガンに対する標的コンビネーション免疫療法 |
| DE69738353T2 (de) | 1996-07-12 | 2009-09-24 | Immunomedics, Inc. | Radiometall-bindende peptide analoge |
| US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
| AU9375698A (en) | 1997-09-03 | 1999-03-22 | Immunomedics Inc. | Fluorination of proteins and peptides for f-18 positron emission tomography |
| US9090668B2 (en) | 2007-03-26 | 2015-07-28 | The University Of Tokyo | Process for synthesizing cyclic peptide compound |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| JP5818237B2 (ja) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
| JP6206943B2 (ja) | 2010-12-03 | 2017-10-04 | 国立大学法人 東京大学 | ペプチドライブラリーの製造方法、ペプチドライブラリー、及びスクリーニング方法 |
| WO2012168944A1 (en) | 2011-06-08 | 2012-12-13 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| WO2013010573A1 (en) * | 2011-07-18 | 2013-01-24 | Universitaet Muenster | Compounds with matrix-metalloproteinase inhibitory activity |
| CA2868408A1 (en) | 2012-03-29 | 2013-10-03 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the bc loop of human pd1 |
| JP2013253842A (ja) | 2012-06-06 | 2013-12-19 | Univ Of Tokyo | ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法 |
| JP6047231B2 (ja) | 2012-06-06 | 2016-12-21 | ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ | β−ヘアピンペプチド模倣薬 |
| SG10201701380TA (en) | 2013-03-15 | 2017-04-27 | Genentech Inc | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| SI3041468T1 (sl) | 2013-09-06 | 2018-10-30 | Aurigene Discovery Technologies Limited | Ciklične peptidomimetične spojine kot imunomodulatorji |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| CA2960778C (en) | 2014-09-11 | 2023-03-07 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) * | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| JP6701217B2 (ja) | 2014-11-25 | 2020-05-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 生物学的製剤の１８ｆ−放射性標識方法および組成物 |
| MX2017006530A (es) | 2014-11-25 | 2017-08-10 | Bristol Myers Squibb Co | Nuevos peptidos que se unen al ligando-1 de muerte programada (pd-l1) para formacion de imagen. |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| KR102526034B1 (ko) | 2016-11-07 | 2023-04-25 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
| US11066445B2 (en) | 2017-06-23 | 2021-07-20 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of PD-1 |
| KR20200058506A (ko) | 2017-10-03 | 2020-05-27 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
-
2017
- 2017-05-17 MX MX2018014028A patent/MX2018014028A/es unknown
- 2017-05-17 RS RS20210499A patent/RS61742B1/sr unknown
- 2017-05-17 JP JP2018560588A patent/JP6953444B2/ja active Active
- 2017-05-17 HU HUE17728696A patent/HUE054306T2/hu unknown
- 2017-05-17 EP EP21152813.8A patent/EP3827849A1/en active Pending
- 2017-05-17 BR BR112018073642-2A patent/BR112018073642A2/pt unknown
- 2017-05-17 MA MA053402A patent/MA53402A/fr unknown
- 2017-05-17 SI SI201730690T patent/SI3458111T1/sl unknown
- 2017-05-17 PT PT177286960T patent/PT3458111T/pt unknown
- 2017-05-17 AU AU2017268291A patent/AU2017268291B2/en active Active
- 2017-05-17 SG SG11201810177VA patent/SG11201810177VA/en unknown
- 2017-05-17 EP EP17728696.0A patent/EP3458111B1/en active Active
- 2017-05-17 DK DK17728696.0T patent/DK3458111T3/da active
- 2017-05-17 KR KR1020187036396A patent/KR102378288B1/ko active IP Right Grant
- 2017-05-17 CN CN201780042462.1A patent/CN109414514B/zh active Active
- 2017-05-17 ES ES17728696T patent/ES2864091T3/es active Active
- 2017-05-17 WO PCT/US2017/033004 patent/WO2017201111A1/en unknown
- 2017-05-17 US US16/098,765 patent/US11103605B2/en active Active
- 2017-05-17 CA CA3024844A patent/CA3024844A1/en active Pending
- 2017-05-17 EA EA201892635A patent/EA038019B1/ru unknown
- 2017-05-17 LT LTEP17728696.0T patent/LT3458111T/lt unknown
- 2017-05-17 PL PL17728696T patent/PL3458111T3/pl unknown
-
2018
- 2018-11-12 IL IL262962A patent/IL262962B/en active IP Right Grant
-
2021
- 2021-04-23 HR HRP20210644TT patent/HRP20210644T8/hr unknown
- 2021-04-29 CY CY20211100375T patent/CY1124241T1/el unknown
- 2021-08-26 US US17/412,612 patent/US20210386876A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210644T1 (hr) | Imunomodulatori za pet-snimanje | |
| Langer | Use of PET imaging to evaluate transporter‐mediated drug‐drug interactions | |
| KleinJan et al. | Fluorescence guided surgery and tracer-dose, fact or fiction? | |
| Maeda et al. | Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor | |
| JP2019520328A5 (hr) | ||
| HRP20170857T1 (hr) | Derivati stirilpiridina i njihova uporaba za vezanje i snimanje amiloidnih naslaga | |
| HRP20210183T1 (hr) | 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate | |
| JP6017964B2 (ja) | 癌診断および撮像 | |
| de Paula Faria et al. | PET imaging of demyelination and remyelination in the cuprizone mouse model for multiple sclerosis: a comparison between [11C] CIC and [11C] MeDAS | |
| EP3634499A1 (en) | Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans | |
| CN104081203A (zh) | 标记的hsp90抑制剂的用途 | |
| JP2012510499A5 (hr) | ||
| Giannelli et al. | Pathological and histological findings associated with the feline lungworm Troglostrongylus brevior | |
| Gofrit et al. | Diagnostic challenges of kidney cancer: a systematic review of the role of positron emission tomography-computerized tomography | |
| BRPI0715783A2 (pt) | fluorescÊncia pràxima do infravermelho usando corantes anÁlogos de Éter fosfolipÍdico em aplicaÇÕes endoscàpicas | |
| Jonsson et al. | Molecular imaging reveals a progressive pulmonary inflammation in lower airways in ferrets infected with 2009 H1N1 pandemic influenza virus | |
| Wall et al. | Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT | |
| WO2008148001A2 (en) | Method of imaging localized infections | |
| WO2014126044A1 (ja) | 発がんリスクの検査方法 | |
| Challapalli et al. | 3′-Deoxy-3′-18 F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer | |
| Gebhardt et al. | Dynamic behaviour of selected PET tracers in embryonated chicken eggs | |
| JP2015528573A5 (hr) | ||
| Sun et al. | Positron emission tomography imaging of cardiomyocyte apoptosis with a novel molecule probe [18F] FP-DPAZn2 | |
| Chondrogiannis et al. | 18F-DOPA PET/computed tomography imaging | |
| Locke et al. | Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma |